VEGF has also been described as a prognostic biomarker for axial SpA, as elevated VEGF levels were associated with higher disease activity (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI)) and increased risk for radiographic progression [43]. The gene discussed is VEGFA; the disease is ankylosing spondylitis.